Drug Trial Radar · NCT07227779
BPaLMZ for TB Meningitis
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
312
Planned (sponsor's estimate)
Start
Jul 28, 2026
Primary completion
Mar 31, 2028
Study completion Sep 30, 2030
Sponsor
- Lead sponsor
- David BoulwareAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Infectious Diseases Institute, Uganda; University of Minnesota; Brighton & Sussex Medical School; Mbarara University of Science and Technology; Radboud University Medical Center; Meningitis Foundation
- First posted
- Nov 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This two-stage study will compare consented research participants with tuberculous meningitis receiving experimental Bedaquiline (B), Pretomanid (Pa), Linezolid (L); Moxifloxacin (M), Pyrazinamide (Z) known as (BPaLMZ) to controls receiving SOC of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E), known as RHZE. The experimental regimen is known as 1BPaLMZ/5PaM.
Conditions
- Tuberculous Meningitis
- HIV
- Meningitis
- TB - Tuberculosis
Interventions
BPaLMZ RegimenDrug
bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24-week SurvivalTime frame: 24 Weeks
- Hierarchical composite endpoint (survival time + functional status)Time frame: 24 Weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Infectious Diseases Institute
Kampala, Uganda · Recruiting
Mbarara University of Science and Technology
Mbarara, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.